IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applican	ıt(s):	John Hansen	Confirmation:	5673	
Serial No	o.:	10/538,918	Group Art Unit:	3761	
Filed:		December 13, 2005	Examiner:	Melanie Jo Hand	
For:		Gelatine-Based Materials as Swabs			
P.O. Box	1450	for Patents 22313-1450			
		INFORMATION DISCLO	SURE STATEME	<u>NT</u>	
Sir:					
	7	This Information Disclosure Stateme	nt is filed in accord	ance with 37 C.F.R.	
§§1.56, 1	.97 an	d 1.98. The items listed on Form PT	O-1449, a copy of	which is enclosed, are	
made of	record	to assist the Patent and Trademark C	Office in its examina	tion of this application.	
The Exa	miner i	s respectfully requested to fully cons	sider the items and t	o independently ascertain	
their teac	ching.				
1.	not in	For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, an English language translation of that item or a portion thereof or a concise explanation of the relevance of that item is enclosed:			
2.	For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, a concise explanation of the relevance of that item is incorporated in the specification of the above-identified application.				
3.	Any copy of the items listed on the enclosed copy of Form PTO-1449 that is not enclosed with this Information Disclosure Statement was previously cited by or submitted to the Patent and Trademark Office in application Serial No, filed				
4.		o fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement nee it is being filed in compliance with:			
		37 C.F.R. §1.97(b)(1), within thre application other than a CPA; or	e months of the filir	ng date of a national	
		37 C.F.R. §1.97(b)(2), within thre national stage as set forth in §1.49			

US 10/538,918 Docket No. 13323-105003

	37 C.F.R. §1.97(b) merits; or	(3), before the mailing date of a first Office action on the	
	37 C.F.R. §1.97(b) filing of an RCE ur	(4) before the mailing date of a first office action after the ider §1.114.	
5.	No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specific in paragraph 4 above but before the mailing date of a final action or a Notice of Allowance (where there has been no prior final action), and is accompanied by one of the certifications pursuant to 37 C.F.R. §1.97(c) set forth in paragraph 9 below.		
6.	A fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement sin it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specified in paragraph 4 above but before the mailing date of a final action or a notice of allowance (where there has been no prior final action):		
	A check in the amo	unt of \$180.00 is enclosed in payment of the fee.	
	Charge the fee to D	eposit Account No. <u>50-3732</u> , Order No. <u>13323-105003</u> .	
7.	A fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Sta it is being filed in compliance with 37 C.F.R. §1.97(d), after the mailing action or a notice of allowance, whichever comes first, but before paymer fee, and is accompanied by:		
	 a. one of the certification below; and 	is pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9	
	 the fee due under 37 C below. 	C.F.R. §1.17(p) which is paid as set forth in paragraph 11	
8.	This Information Disclosure Statement is being filed in compliance with:		
	information cited in one claim unpatent)(3) or §1.313(c)(1), after the issue fee has been paid and this Information Disclosure Statement may render at least able and is accompanied by the attached Petition To ion From Issue and fee pursuant to 37 C.F.R. §1.17(h);	
	information cited in in a Request for Co upon abandonment	(2) or §1.313(c)(3), after the issue fee has been paid and this Information Disclosure Statement is to be considered ntinued Examination (RCE) or a Continuation application of the instant application and is accompanied by the b Withdraw Application From Issue and fee pursuant to 37	
	c. The fee due under in below.	37 C.F.R. §§1.17(h) is paid as set forth in paragraph 11	
9.		em of information contained in this Information Disclosure a communication from a foreign patent office in a	

US 10/538,918 Docket No. 13323-105003

	counterpart foreign application not mo Information Disclosure Statement.	ore than three months prior to the filing of this				
	I hereby certify that no item of information in the Information Disclosure Statement filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.					
10.	This document is accompanied by \square a Search Report \square Communication which was cited in a corresponding \square PCT or \square Foreign counterpart application.					
11.	A check in the amount of \$ is enclosed in payment of the fees due under 37 C.F.R. $\$\$1.17(h)$ and $1.17(p)$.					
	Charge any fees due under 37 C.F.R. 50-3732, Order No	§§1.17(h) and 1.17(p) to Deposit Account No.				
\boxtimes	The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 50-3732, Order No. 13323-105003.					
		Respectfully submitted, KING & SPALDING LLP				
Dated: C	October 13, 2009 By:	/michael willis/ Michael A. Willis				
orresno	ondence Address:	Reg. No. 53,913				
King & Spalding LLP						
185 Avenue of the Americas						
New York, NY 10036						

212-556-2100 Telephone 212-556-2222 Facsimile